Federal Register / Vol. 75, No. 172 / Tuesday, September 7, 2010 / Notices 54349 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable materials, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, NIDA 

Clinical Science Conference Grant (R13) 

Review. 

Date: September 29, 2010. 

Time: 9 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6101 

Executive Boulevard, Rockville, MD 20852. 

(Virtual Meeting) 

Contact Person: Gerald L. McLaughlin, 

PhD, Scientific Review Administrator, Office 

of Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, Room 220, MSC 

8401, 6101 Executive Blvd., Bethesda, MD 

20892–8401. 301–402–6626. 

gm145a@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, NIDA 

B/Start Small Grant Review. 

Date: October 20, 2010. 

Time: 9 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6101 

Executive Boulevard, Rockville, MD 20852. 

(Virtual Meeting) 

Contact Person: Gerald L. McLaughlin, 

PhD, Scientific Review Administrator, Office 

of Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, Room 220, MSC 

8401, 6101 Executive Blvd., Bethesda, MD 

20892–8401. 301–402–6626. 

gm145a@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Initial Review Group, Training 

and Career Development Subcommittee. 

Date: November 3–5, 2010. 

Time: 9 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Ritz-Carlton Hotel, 1150 22nd Street, 

NW., Rockville, MD 20852, Washington, DC 

20037. 

Contact Person: Kristen V. Huntley, PhD, 

Scientific Review Administrator, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, Room 220, MSC 

8401, 6101 Executive Boulevard, Bethesda, 

MD 20892–8401. 301–435–1433. 

huntleyk@mail.nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, NIDA 

I/Start Small Grant Review. 

Date: November 10, 2010. 

Time: 9 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6101 

Executive Boulevard, Rockville, MD 20852. 

(Virtual Meeting.) 

Contact Person: Gerald L. McLaughlin, 

PhD, Scientific Review Administrator, Office 

of Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, Room 220, MSC 

8401, 6101 Executive Blvd., Bethesda, MD 

20892–8401. 301–402–6626. 

gm145a@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos.: 93.279, Drug Abuse and 

Addiction Research Programs, National 

Institutes of Health, HHS) 

Dated: August 31, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–22183 Filed 9–3–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Negotiated Rulemaking Committee on 

Designation of Medically Underserved 

Populations and Health Professional 

Shortage Areas; Notice of Meeting 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), notice is hereby given 

of the following meeting: 

Name: Negotiated Rulemaking 

Committee on Designation of Medically 

Underserved Populations and Health 

Professional Shortage Areas. 

Date and time: September 22, 2010, 

9:30 a.m. to 5 p.m. 

September 23, 2010, 9 a.m. to 4:30 

p.m. 

September 24, 2010, 9 a.m. to12 p.m. 

Place: The Legacy Hotel, Georgetown 

Room, 1775 Rockville Pike, Rockville, 

Maryland 20852, (301) 881–2300. 

Status: The meeting will be open to 

the public. 

Purpose: The purpose of the 

Negotiated Rulemaking Committee on 

Designation of Medically Underserved 

Populations and Health Professional 

Shortage Areas is to establish a 

comprehensive methodology and 

criteria for Designation of Medically 

Underserved Populations and Primary 

Care Health Professional Shortage 

Areas, using a Negotiated Rulemaking 

(NR) process. It is hoped that use of the 

NR process will yield a consensus 

among technical experts and 

stakeholders on a new rule, which will 

then be published as an Interim Final 

Rule in accordance with Section 5602 of 

Public Law 111–148, the Patient 

Protection and Affordable Care Act of 

2010. 

Agenda: The meeting will be held on 

Wednesday, September 22, Thursday, 

September 23 and Friday, September 24, 

and will include an orientation to the 

negotiated rulemaking process, ground 

rules for Committee operations, and an 

overview of the key topics on which the 

Committee will explore and seek 

consensus. The Friday morning meeting 

will include development of the agenda 

for the next meeting, as well as an 

opportunity for public comment. 

FOR FURTHER INFORMATION CONTACT: For 

more information, please contact Lauren 

Krantz, Office of Shortage Designation, 

Bureau of Health Professions, Health 

Resources and Services Administration, 

Room 9A–18, Parklawn Building, 5600 

Fishers Lane, Rockville, Maryland 

20857, Telephone (301) 443–9027, Email lkrantz@hrsa.gov, or visit http:// 

bhpr.hrsa.gov/shortage/. 

SUPPLEMENTARY INFORMATION: Requests 

from the public to make oral comments 

or to provide written comments to the 

Committee should be sent to Lauren 

Krantz at the contact address above at 

least 10 days prior to the meeting. The 

meetings will be open to the public as 

indicated below, with attendance 

limited to space available. Individuals 

who plan to attend and need special 

assistance, such as sign language 

interpretation or other reasonable 

accommodations, should notify the 

Contact Person listed above at least 10 

days prior to the meeting. Members of 

the public will have the opportunity to 

provide comments at the Friday 

morning meeting. 

Dated: September 1, 2010. 

Sahira Rafiullah, 

Director, Division of Policy and Information 

Coordination. 

[FR Doc. 2010–22194 Filed 9–3–10; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–D–0007] 

Animal Models—Essential Elements To 

Address Efficacy Under the Animal 

Rule; Notice of Public Meeting; and 

Reopening of Comment Period 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of public meeting; and 

reopening of comment period. 

SUMMARY: The Food and Drug 

Administration’s (FDA or agency) 

Center for Biologics Evaluation and 

Research (CBER) and Center for Drug 

Evaluation and Research (CDER) are 

announcing a public meeting to solicit 

comments and concerns of industry, 

other government agencies, and 

interested parties on the regulatory and 

scientific challenges as addressed in the 

draft document entitled ‘‘Guidance for 


wwoods2 on DSK1DXX6B1PROD with NOTICES_PART 1